Phase 1, two-part, multicenter, non-randomized, open-label, multiple dose, first-in-human study of DS-1062a in subjects with advanced solid tumors

Trial Profile

Phase 1, two-part, multicenter, non-randomized, open-label, multiple dose, first-in-human study of DS-1062a in subjects with advanced solid tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs DS-1062a (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 28 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top